Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Multi-Dose Open-Label Phase II Study of BMS-663513 (Anti-CD137) in Melanoma
2007-003993-24Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of urelumab in melanoma (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Progression-free survival rate at 6 months. Started Jan 2008; status: completed.
02
Drugs
urelumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2007-003993-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003993-24.